Phase I Clinical Study of HRS-2189 in the Treatment of Patients With Advanced Malignant Tumors

Advanced Malignant Tumor Clinical Trial

Official title:

A Single Arm, Open, Multicenter Phase I Clinical Study on the Safety, Tolerance, and Pharmacokinetics of HRS-2189 Single Drug in Patients With Advanced Malignant Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05851092
• Other study ID #: HRS-2189-I-101
• Status: Recruiting
• Phase: Phase 1
• Start date: May 26, 2023
• Est. completion date: December 31, 2025

Study information

• Verified date: April 2023
• Source: Shandong Suncadia Medicine Co., Ltd.
• Contact: Xia Zhang
• Phone: +86-0518-81220121
• Email: xia.zhang[@]hengrui.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is a multi center, open label, dose increasing/dose expanding/efficacy expanding phase I clinical trial aimed at evaluating the safety, tolerance, PK characteristics, and anti-tumor efficacy characteristics of HRS-2189 single drug in patients with advanced malignant solid tumors. This study was divided into three stages: dose escalation, dose expansion, and efficacy expansion.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: December 31, 2025
• Est. primary completion date: December 31, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Volunteer to participate in this study, sign an informed consent form, have good compliance, and can cooperate with follow-up

2. Age = 18 years old (including boundary value, calculated based on the date of signing informed consent), Male or female

3. ECOG score: 0-1

4. Expected survival = 12 weeks

5. Local recurrent or metastatic advanced malignant solid tumor confirmed by histopathology or cytopathology and not resectable, and currently fails to undergo standard treatment or has no standard treatment plan

6. If enrolled in ER positive and HER2 negative female breast cancer subjects, they need to meet the criteria defined in the guidelines of the American Association of Clinical Oncology/American College of Pathologists

7. Baseline presence of at least one extracranial measurable lesion that meets the RECIST v1.1 standard

8. The functional level of important organs is basically normal, meeting the requirements of the scheme

9. Previous treatment: Before the first medication in this study, the interval between receiving nitrosourea or mitomycin C = 6 weeks; Receiving cytotoxic drugs, endocrine therapy, immunotherapy, targeted therapy, surgical interval (except puncture biopsy or PICC catheterization or PORT infusion port catheterization) or other clinical studies with the last medication = 4 weeks; Interval from the end of radiotherapy = 2 weeks

10. Adverse events caused by other treatments for the subject returned to a severity level of NCI-CTCAE V5.0 = 1 (excluding hair loss and other adverse events judged tolerable by the investigator)

11. Female subjects with fertility must agree to use highly effective contraception during the study treatment period and within 7 months after the last medication; Male subjects must agree to use highly effective contraception during the study treatment period and 4 months after the last medication; Female subjects with fertility must have a negative serum HCG test within 7 days before the first medication in the study, and must be in non lactation. If the serum HCG is weakly positive, it is necessary for the researcher to evaluate and judge it as a non pregnant state, and urine HCG should be tested before medication, with a negative result

12. Volunteer to participate in this clinical trial, willing and able to follow the procedures related to clinical visits and research, understand the research procedures, and have signed informed consent

Exclusion Criteria:

1. Subjects with cancerous meningitis or untreated central nervous system metastasis

2. Uncontrolled pleural, abdominal, and pericardial effusion

3. Clinical symptoms or diseases of the heart that are not well controlled

4. Arterial/venous thrombotic events occurred within 6 months before the first medication administration

5. Active infection or unexplained fever>38.5 ° C occurred within 4 weeks before or on the day of the first medication (subjects with tumor fever are judged by the investigator to be included in the study)

6. Subjects with congenital or acquired immune dysfunction (such as HIV infected persons); Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation

7. Subject has active hepatitis

8. Subjects had other malignant tumors within the past 3 years, except for fully treated basal or squamous cell skin cancer or cervical carcinoma in situ

9. Those who are unable to swallow tablets normally or have gastrointestinal dysfunction that may affect drug absorption according to the judgment of the researcher

10. Patients participating in the QT/QTc study have used any medication that has the risk of prolonging the QT/QTc interval or causing torsade de pointe (TdP) within 4 weeks before the first medication, have a previous history of congenital QT interval prolongation syndrome or a family history of QT interval prolongation, have an implanted pacemaker or automatic implantable cardioverter defibrillator, and cannot correct electrolyte disturbances that affect the QT/QTc study

11. Pregnant and lactating women, or planning to become pregnant during the study period

12. According to the judgment of the researcher, the subject has other factors that may lead to the forced termination of this study

Related Conditions & MeSH terms

• Advanced Malignant Tumor
• Neoplasms

Intervention

Drug:
• HRS-2189 Tablets
HRS-2189 Tablets

Locations

Country	Name	City	State
China	Harbin Medical University Cancer Hospital	Harbin	Heilongjiang

Sponsors (1)

Lead Sponsor	Collaborator
Shandong Suncadia Medicine Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	AEs+SAEs		from the first drug administration to within 30 days for the last treatment dose
Primary	Dose limited toxicity (DLT) of HRS-2189		up to 35 days
Primary	Maximum tolerated dose(MTD)of HRS-2189		up to 35 days
Primary	Recommended Phase II Dose (RP2D) of HRS-2189		up to 35 days
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Cmax		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Tmax		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: AUC0-t		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: AUC0-inf		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Cmax,ss		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Tmax,ss		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Cmin,ss		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: AUCss		2 months
Secondary	Evaluation of pharmacokinetic parameter of HRS-2189: Rac		2 months
Secondary	Bioavailability of HRS-2189 on an empty stomach and after meals		up to 9 days
Secondary	Objective Response Rate (ORR)	Number of responders Assessed by Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) for target lesions assessed by CT or MRI	every 8 weeks since Day 8 administration,an average of 1 year
Secondary	Duration of response (DoR)	Time from documentation of tumor response to disease progression assessed among patients who had an objective response	every 8 weeks since Day 8 administration,an average of 1 year
Secondary	Disease control rate (DCR)	Complete response + Partial response + Stable disease (CR+PR+SD) based on RECIST 1.1	every 8 weeks since Day 8 administration,an average of 1 year
Secondary	Progression free survival(PFS)	The time from enrollment to the progression of tumors (in any aspect) or death (for any reason)	every 8 weeks since Day 8 administration,an average of 1 year